MTOR and diabetic retinopathy: As we continue to unravel the complexity of the initiating factors that contribute to the microangiopathy observed in progressive diabetic retinopathy and gain further understanding of the natural progression of the disease it is imperative that emerging therapeutics like mTOR inhibitors be well contemplated in the context of their mechanism of action, stage progression of the retinopathy, and the critical timing of pharmacological intervention.